4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

Date: July 18, 2017
Pages: 43
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: 4FF8D61A4D9EN
Leaflet:

Download PDF Leaflet

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including resminostat, 4SC-202, and 4SC-208. The company’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG Key Recent Developments

Nov 10,2016: 4SC provides Q3 2016 update
Oct 21,2016: 4SC: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the End of 2016
Sep 21,2016: Dr Jason Loveridge appointed new CEO of 4SC
Aug 11,2016: 4SC provides operational and financial update for Q2 and 6M 2016
May 12,2016: 4SC reports on key events in Q1 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

4SC AG - Key Facts
4SC AG - Key Employees
4SC AG - Key Employee Biographies
4SC AG - Major Products and Services
4SC AG - History
4SC AG - Company Statement
4SC AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

4SC AG - Business Description
4SC AG - Corporate Strategy
4SC AG - SWOT Analysis
SWOT Analysis - Overview
4SC AG - Strengths
4SC AG - Weaknesses
4SC AG - Opportunities
4SC AG - Threats
4SC AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
4SC AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 10, 2016: 4SC provides Q3 2016 update
Oct 21, 2016: 4SC: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the End of 2016
Sep 21, 2016: Dr Jason Loveridge appointed new CEO of 4SC
Aug 11, 2016: 4SC provides operational and financial update for Q2 and 6M 2016
May 12, 2016: 4SC reports on key events in Q1 2016
Mar 30, 2016: 4SC announces results for financial year 2015

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

4SC AG, Key Facts
4SC AG, Key Employees
4SC AG, Key Employee Biographies
4SC AG, Major Products and Services
4SC AG, History
4SC AG, Subsidiaries
4SC AG, Key Competitors
4SC AG, Ratios based on current share price
4SC AG, Annual Ratios
4SC AG, Annual Ratios (Cont...1)
4SC AG, Interim Ratios
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
4SC AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

4SC AG, Performance Chart (2012 - 2016)
4SC AG, Ratio Charts
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

SWOG
MediGene AG
Galapagos NV
Biovest International Inc
Apitope International NV
Skip to top


Ask Your Question

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: